Nishinomiya, Japan

Hiroshi Ohtsuka


Average Co-Inventor Count = 6.5

ph-index = 2

Forward Citations = 87(Granted Patents)


Location History:

  • Nishinomiya, JP (1993)
  • Hyogo, JP (1993)

Company Filing History:


Years Active: 1993

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Hiroshi Ohtsuka: Innovator in Monoclonal Antibody Development

Introduction

Hiroshi Ohtsuka is a prominent inventor based in Nishinomiya, Japan. He has made significant contributions to the field of biotechnology, particularly in the development of human monoclonal antibodies. His work has implications for therapeutic and prophylactic treatments against infectious diseases.

Latest Patents

Hiroshi Ohtsuka holds 2 patents related to human monoclonal antibodies. His latest patents include a human monoclonal antibody that exhibits both prophylactic and therapeutic effects against infections caused by Pseudomonas aeruginosa. The epitope of this antibody is located in the outer core moiety of the lipopolysaccharide (LPS) of the microorganism. Additionally, he has developed a hybridoma that produces this human monoclonal antibody, along with processes for preparing both the antibody and the hybridoma. Another patent focuses on a human monoclonal antibody that targets infectious diseases caused by Pseudomonas aeruginosa serotypes A and H. This antibody's epitope is situated at a common structure in the O-antigen of these serotypes. The patent also includes a hybridoma producing this antibody and the processes for their preparation.

Career Highlights

Throughout his career, Hiroshi Ohtsuka has worked with notable companies such as Sumitomo Chemical Company, Limited and Sumitomo Pharmaceuticals Company Limited. His experience in these organizations has contributed to his expertise in the field of biotechnology and antibody development.

Collaborations

Hiroshi Ohtsuka has collaborated with esteemed colleagues, including Hiroshi Ochi and Shinichi Yokota. These collaborations have likely enhanced his research and development efforts in monoclonal antibody technology.

Conclusion

Hiroshi Ohtsuka's innovative work in the field of human monoclonal antibodies has the potential to significantly impact the treatment of infectious diseases. His patents and collaborations reflect his dedication to advancing biotechnology.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…